Vividion Therapeutics withdrew its plans for an initial public offering after announcing earlier this month that it would be acquired by Bayer for up to $2 billion, Renaissance Capital reported.
The company was founded in 2013 and had disclosed plans in June to raise $100 million and list on the Nasdaq under the symbol VVID.










(All Rights Reserved)